Viktor Grünwald

19.7k total citations · 5 hit papers
328 papers, 10.4k citations indexed

About

Viktor Grünwald is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Viktor Grünwald has authored 328 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 257 papers in Pulmonary and Respiratory Medicine, 145 papers in Oncology and 129 papers in Molecular Biology. Recurrent topics in Viktor Grünwald's work include Renal cell carcinoma treatment (189 papers), Renal and related cancers (98 papers) and Cancer Genomics and Diagnostics (83 papers). Viktor Grünwald is often cited by papers focused on Renal cell carcinoma treatment (189 papers), Renal and related cancers (98 papers) and Cancer Genomics and Diagnostics (83 papers). Viktor Grünwald collaborates with scholars based in Germany, United States and France. Viktor Grünwald's co-authors include Camillo Porta, Bernard Escudier, Manuel Hidalgo, Robert J. Motzer, Thomas E. Hutson, Alain Ravaud, Sergio Bracarda, Robert A. Figlin, Stéphane Oudard and John A. Thompson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Viktor Grünwald

298 papers receiving 10.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
Phase 3 trial of everolimus for metastatic renal cell carcinoma

2010 903 citations Robert J. Motzer, Bernard Escudier et al. profile →
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2019 774 citations Bernard Escudier, Camillo Porta et al. profile →
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2024 96 citations Laurence Albigès, Axel Bex et al. profile →
Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches

2023 80 citations Ken Herrmann, Boris Hadaschik et al. profile →

Peers

Countries citing papers authored by Viktor Grünwald

Since Specialization

Citations

This map shows the geographic impact of Viktor Grünwald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viktor Grünwald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viktor Grünwald more than expected).

Fields of papers citing papers by Viktor Grünwald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viktor Grünwald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viktor Grünwald. The network helps show where Viktor Grünwald may publish in the future.

Co-authorship network of co-authors of Viktor Grünwald

This figure shows the co-authorship network connecting the top 25 collaborators of Viktor Grünwald. A scholar is included among the top collaborators of Viktor Grünwald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Viktor Grünwald. Viktor Grünwald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study 2025 ·European Journal of Cancer ·Viktor Grünwald, Axel Bex, Sylvie Rottey, (unknown), Giuseppe Procopio, Guillermo Velasco, Bohuslav Melichar, Jens Bedke, Lisa Pickering, (unknown), Manuela Schmidinger, Aristotelis Bamias, Marine Gross‐Goupil, Camillo Porta, Philippe Barthélémy, (unknown), Laurence Albigès	1
2	On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC 2025 ·Oncology and Therapy ·Bernadett Szabados, Félix Guerrero‐Ramos, Enrique Grande, Petros Grivas, Viktor Grünwald, (unknown), Syed A. Hussain, Girish S. Kulkarni, Anne Wilson, Neal D. Shore, Srikala S. Sridhar, (unknown), (unknown), (unknown), (unknown), Rosemary E. Teresi, Tilman Todenhöfer	0
3	CD70-targeted cancer theranostics: Progress and challenges 2025 ·Med ·Weijun Wei, Viktor Grünwald, (unknown)	4
4	Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC 2025 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), (unknown), (unknown), Kim M. Pabst, Viktor Grünwald, Kuangyu Shi, (unknown), (unknown), Lale Umutlu, Ken Herrmann, Robert Seifert, Wolfgang P. Fendler	1
5	The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression 2024 ·European Journal of Cancer ·(unknown), Markus Eckstein, Manuel Ritter, Peter Brossart, Michael Hölzel, Viktor Grünwald, Niklas Klümper	3
6	Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients 2024 ·Scientific Reports ·Johannes Uhlig, Annemarie Uhlig, Hari A. Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael E. Hurwitz, (unknown), Peter A. Humphrey, Viktor Grünwald, Hyun S. Kim	0
7	Prognostic Implications of⁶⁸Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors 2024 ·Journal of Nuclear Medicine ·Masao Watanabe, Wolfgang P. Fendler, Hong Grafe, Nader Hirmas, Rainer Hamacher, (unknown), Kim M. Pabst, Hubertus Hautzel, Clemens Aigner, Stefan Kasper, Bastian von Tresckow, Martin Stuschke, Sherko Kümmel, (unknown), Boris Hadaschik, Viktor Grünwald, Fadi Zarrad, Jens T. Siveke, Ken Herrmann, Manuel Weber	9
8	Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer 2024 ·JAMA Oncology ·Randy F. Sweis, Pablo Gajate, Rafael Morales‐Barrera, Jae‐Lyun Lee, Andrea Necchi, Filippo de Braud, Nicolas Penel, Viktor Grünwald, Marco Maruzzo, Johannes Meran, (unknown), Weichao Bao, Yinghui Zhou, Peter Ellinghaus, Jonathan E. Rosenberg	6
9	Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer 2024 ·Cancer Medicine ·(unknown), (unknown), (unknown), (unknown), Damian J. Ralser, Marieta Toma, Glen Kristiansen, Oliver Hahn, Sabrina Zechel, Viktor Grünwald, Tobias Bald, (unknown), Torsten Pietsch, Manuel Ritter, (unknown), Markus Eckstein, (unknown), Philipp Krausewitz, Niklas Klümper	3
10	Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. 2024 ·Journal of Clinical Oncology ·Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas E. Hutson, Sun Young Rha, Jaime R. Merchan, Eric Winquist, Howard Gurney, Viktor Grünwald, Saby George, (unknown), Joseph E. Burgents, Răzvan Cristescu, Y. Narita, Cixin He, Zi-Ming Zhao, Chinyere E. Okpara, Yukinori Minoshima, Toni K. Choueiri	7
11	On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy 2023 ·European Urology Oncology ·(unknown), Viktor Grünwald, Tobias Bald, Manuel Ritter, Peter Brossart, Yoshihiko Tomita, Arndt Hartmann, (unknown), Markus Eckstein, Niklas Klümper	7
12	Real world data on the use of nivolumab and ipilimumab combination therapy or nivolumab monotherapy in the treatment of renal cell carcinoma: Interim results from the non-interventional study (NIS) NORA 2020 ·European Urology Open Science ·Marc‐Oliver Grimm, Viktor Grünwald, (unknown), (unknown), (unknown), Jens Bedke	1
13	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG) 2020 ·BMJ Open ·Leopold Hentschel, Stephan Richter, Hans‐Georg Kopp, Bernd Kasper, Annegret Kunitz, Viktor Grünwald, Torsten Keßler, Jens M. Chemnitz, Uwe Pelzer, Ulrich S. Schuler, (unknown), Andrea Schilling, Beate Hornemann, (unknown), Martin Bornhäuser, Markus K. Schuler	6
14	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’ 2018 ·European Journal of Cancer ·Patrick Schöffski, Agnieszka Woźniak, Michael Leahy, Steinar Aamdal, Piotr Rutkowski, Sebastian Bauer, Stephan Richter, Viktor Grünwald, Maria Dêbiec‐Rychter, Raf Sciot, Birgit Geoerger, Sandrine Marréaud, Sandra Collette, Axelle Nzokirantevye, Sandra J. Strauss	32
15	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial 2017 ·European Journal of Cancer ·Patrick Schöffski, Agnieszka Woźniak, Bernard Escudier, Piotr Rutkowski, Alan Anthoney, Sebastian Bauer, Jozef Šufliarský, Carla van Herpen, Lars H. Lindner, Viktor Grünwald, Branko Zakotnik, Evelyne Lerut, Maria Dêbiec‐Rychter, Sandrine Marréaud, Michela Lia, Tiana Raveloarivahy, Sandra Collette, Laurence Albigès	94
16	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents 2017 ·Oncology ·Paolo Grassi, Ludovic Doucet, (unknown), Viktor Grünwald, Bohuslav Melichar, Luca Galli, Ugo De Giorgi, Roberto Sabbatini, Cinzia Ortega, Matteo Santoni, Aristotelis Bamias, Elena Verzoni, Lisa Derosa, Hana Študentová, Luca Porcu, Filippo de Braud, Camillo Porta, Giuseppe Procopio	3
17	Vorinostat in refractory soft tissue sarcomas – Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO) 2016 ·European Journal of Cancer ·Thomas Schmitt, Regine Mayer‐Steinacker, Frank Mayer, Viktor Grünwald, J. Schütte, Jörg T. Hartmann, Bernd Kasper, Johannes Hüsing, Jacek Hajda, (unknown), Gunhild Mechtersheimer, Gerd Mikus, Jürgen Burhenne, Lorenz Lehmann, Christoph E. Heilig, Anthony D. Ho, Gerlinde Egerer	32
18	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer 2014 ·Clinical Cancer Research ·Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen‐Chuan Ou, Daniel Castellano, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, (unknown), Nicoletta Pirotta, Matthew Squires, Michael Shi, Eric Angevin	49
19	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial breakdown → 2008 ·The Lancet ·Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud	2339
20	Testing the importance of p27 degradation by the SCF ^skp2 pathway in murine models of lung and colon cancer 2006 ·Proceedings of the National Academy of Sciences ·(unknown), Carrie M. Garrett-Engele, Uta Kossatz-Boehlert, Xueyan Chen, Eduardo Firpo, Viktor Grünwald, Kenji Kamino, Ludwig Wilkens, Ulrich Lehmann, Jan Buer, Robert Geffers, Stefan Kubicka, Michael P. Manns, Peggy L. Porter, James M. Roberts, Nisar P. Malek	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact